JP2022502471A5 - - Google Patents
Info
- Publication number
- JP2022502471A5 JP2022502471A5 JP2021520202A JP2021520202A JP2022502471A5 JP 2022502471 A5 JP2022502471 A5 JP 2022502471A5 JP 2021520202 A JP2021520202 A JP 2021520202A JP 2021520202 A JP2021520202 A JP 2021520202A JP 2022502471 A5 JP2022502471 A5 JP 2022502471A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- patient
- approximately
- cannabidiol
- tetrahydrocannabinol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862743839P | 2018-10-10 | 2018-10-10 | |
| US62/743,839 | 2018-10-10 | ||
| PCT/US2019/055662 WO2020077103A1 (en) | 2018-10-10 | 2019-10-10 | Methods and formulations for treating chemotherapy-induced nausea and vomiting |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022502471A JP2022502471A (ja) | 2022-01-11 |
| JP2022502471A5 true JP2022502471A5 (OSRAM) | 2022-10-17 |
Family
ID=68345091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021520202A Pending JP2022502471A (ja) | 2018-10-10 | 2019-10-10 | 化学療法誘発性の悪心および嘔吐を治療するための方法および製剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20200113847A1 (OSRAM) |
| EP (1) | EP3863614A1 (OSRAM) |
| JP (1) | JP2022502471A (OSRAM) |
| KR (1) | KR20210116432A (OSRAM) |
| AU (1) | AU2019357608A1 (OSRAM) |
| BR (1) | BR112021006858A2 (OSRAM) |
| CA (1) | CA3115985A1 (OSRAM) |
| CL (1) | CL2021000882A1 (OSRAM) |
| CO (1) | CO2021005797A2 (OSRAM) |
| MX (1) | MX2021004138A (OSRAM) |
| PE (1) | PE20211198A1 (OSRAM) |
| WO (1) | WO2020077103A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200360292A1 (en) * | 2019-05-16 | 2020-11-19 | Aegis Therapeutics, Llc | Oil-soluble drug containing compositions and methods of use thereof |
| CN115968278A (zh) * | 2020-05-18 | 2023-04-14 | 麦氏生物科技有限公司 | 脂质-聚合物组合物及使用方法 |
| CA3173494A1 (en) * | 2020-09-24 | 2022-03-31 | Michael Foster DAVIS | Cannabinoid composition comprising at least 50% carrier |
| JP7752233B2 (ja) * | 2022-07-06 | 2025-10-09 | アバンサール センディリアン ベルハッド | 親油性化合物の改善された経口バイオアベイラビリティを有する自己乳化薬物送達配合物 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH695661A5 (de) * | 2001-03-06 | 2006-07-31 | Forsch Hiscia Ver Fuer Krebsfo | Pharmazeutische Zusammensetzung. |
| US20040248970A1 (en) * | 2003-04-10 | 2004-12-09 | Webster G.R. Barrie | CBD-delta8-THC composition |
| US20050191343A1 (en) * | 2003-11-26 | 2005-09-01 | Shire Laboratories, Inc. | Micellar systems useful for delivery of lipophilic or hydrophobic compounds |
| EP1881757A4 (en) * | 2005-05-13 | 2008-09-10 | Unimed Pharmaceuticals Inc | DRONABINOL TREATMENT OF CHEMOTHERAPY-INDUCED POSSIBLE INCOMPATIBILITY AND ILLUSTRATION |
| TWI366460B (en) * | 2005-06-16 | 2012-06-21 | Euro Celtique Sa | Cannabinoid active pharmaceutical ingredient for improved dosage forms |
| US20160279073A1 (en) * | 2013-10-31 | 2016-09-29 | Full Spectrum Laboratories, Ltd. | Terpene and cannabinoid formulations |
| WO2017203529A1 (en) * | 2016-05-24 | 2017-11-30 | Bol Pharma Ltd. | Compositions comprising cannabidiol and hyaluronic acid for treating inflammatory joint diseases |
| WO2018058235A1 (en) * | 2016-09-27 | 2018-04-05 | CannTab Therapeutics Limited | Sustained release cannabinoid formulations |
| EP3525764A4 (en) * | 2016-10-12 | 2020-05-13 | Columbia Care LLC | ORAL COMPOSITION OF EXTRACTED CANNABINOIDS AND METHOD FOR USE THEREOF |
| EP3565539A4 (en) * | 2017-01-03 | 2020-08-12 | Receptor Holdings, Inc. | MEDICINAL COMPOUNDS AND NUTRITIONAL SUPPLEMENTS |
| CN110636834A (zh) * | 2017-02-15 | 2019-12-31 | 分子浸剂有限公司 | 制剂 |
| US10307392B2 (en) * | 2017-10-21 | 2019-06-04 | Alexander Kariman | Compound and method for treatment of diseases and disorders |
| WO2019100007A1 (en) * | 2017-11-17 | 2019-05-23 | Tilray, Inc. | Cannabinoid compositions |
| EP4417252A3 (en) * | 2018-02-23 | 2024-11-06 | Yuzu LV LLC | Cannabis based therapeutic and method of use |
| BR112021001406A2 (pt) * | 2018-07-31 | 2021-04-27 | AusCann Group Holdings Ltd | composições farmacêuticas auto-emulsificantes sólidas |
-
2019
- 2019-10-10 WO PCT/US2019/055662 patent/WO2020077103A1/en not_active Ceased
- 2019-10-10 US US16/598,696 patent/US20200113847A1/en not_active Abandoned
- 2019-10-10 EP EP19794850.8A patent/EP3863614A1/en not_active Withdrawn
- 2019-10-10 CA CA3115985A patent/CA3115985A1/en active Pending
- 2019-10-10 KR KR1020217013980A patent/KR20210116432A/ko not_active Withdrawn
- 2019-10-10 PE PE2021000497A patent/PE20211198A1/es unknown
- 2019-10-10 BR BR112021006858-9A patent/BR112021006858A2/pt not_active Application Discontinuation
- 2019-10-10 JP JP2021520202A patent/JP2022502471A/ja active Pending
- 2019-10-10 AU AU2019357608A patent/AU2019357608A1/en not_active Abandoned
- 2019-10-10 MX MX2021004138A patent/MX2021004138A/es unknown
-
2021
- 2021-04-09 CL CL2021000882A patent/CL2021000882A1/es unknown
- 2021-04-30 CO CONC2021/0005797A patent/CO2021005797A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003240824B2 (en) | Transmucosal delivery of cannabinoids | |
| AU2003227735B2 (en) | Film-shaped mucoadhesive administration form for administering cannabis active ingredients | |
| US20040110828A1 (en) | Tetrahydrocannabinol compositions and methods of manufacture and use thereof | |
| JP2022180461A5 (OSRAM) | ||
| US11318093B2 (en) | Dental topical anesthetic gel | |
| CO5170471A1 (es) | Tabletas de liberacion modificada que incluyen amoxilina y clavulanato de potasio | |
| KR19980069961A (ko) | 항문직장 및 결장 질병의 제어 및 치료를 위한 신규 약제학적조성물 및 그 제조방법 | |
| JP7333405B2 (ja) | 経口薄フィルム | |
| US20110160264A1 (en) | Orally administrable film dosage forms containing ondansetron | |
| EP3449915A1 (en) | Composition containing cannabinoids for use in a method for the treatment of atopic dermatitis | |
| US20040229939A1 (en) | Tetrahydrocannabinol compositions and methods of manufacture and use thereof | |
| WO2018004576A3 (en) | A fast acting orally disintegrating film for administration of local anesthesia | |
| JP2022502471A (ja) | 化学療法誘発性の悪心および嘔吐を治療するための方法および製剤 | |
| JP2019514990A5 (OSRAM) | ||
| JP2009508869A (ja) | シトクロムｐ４５０についての基質活性を持つ上皮内及び全体的な曝露の増大のための方法、及び膜流出系それに次ぐ鞘及び口腔の管理 | |
| JP2025511402A5 (OSRAM) | ||
| CA3151070A1 (en) | Orally dissolving mucoadhesive films utilizing menthol and l-arginine to enhance the bioavailability of cannabinoids | |
| CN117545478A (zh) | 用于治疗慢性疼痛的透皮药物制剂 | |
| WO2015157729A1 (en) | Pharmaceutical formulations an comprising analgesic agent, a nonsteroidal anti-inflammatory agent, a gastric acid production suppressant and an anti-nauseant | |
| JP2011507853A5 (OSRAM) | ||
| RU2013105513A (ru) | Производные 1-аминоалкилциклогексана для лечения воспалительных заболеваний кожи | |
| CN109419773B (zh) | 复合纳米脂质给药系统及其对妇科肿瘤的治疗作用 | |
| WO2010019279A8 (en) | Pharmaceutical compositions configured to deter dosage form splitting | |
| JP2003512421A5 (OSRAM) | ||
| CN105193726B (zh) | 一种治疗灰指甲的药物组合物 |